Testing GD2 CAR T Cells in Children and Young Adults With Brain Tumors
Official title: GD2-CAR T Cells for Pediatric Brain Tumours
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests changed immune cells in young people whose brain tumor came back.
Read our full plain-language summary
What the trial team says
The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.
Key facts
- Registry number
- NCT05298995
- Stage of testing
- Phase 1
- Conditions studied
- Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor, High Grade Glioma, Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma, Brain Tumor Adult
Where it is running
This trial lists 1 site.
-
Italy
- Ospedale Pediatrico Bambino Gesù (Roma)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.